Market news

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following

EMERYVILLE, Calif., August 11, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lympho

EMERYVILLE, Calif., August 03, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lymph

EMERYVILLE, Calif., July 29, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lympho

EMERYVILLE, Calif., July 24, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (